Sinopharm Group CoSHTDF -2.67%78 ROA % is 1.84% as of Dec. 2025, which is 25% below its 10-year median of 2.45. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 120 Medical Distribution companies, Sinopharm Group Co ranks worse than 58.33% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sinopharm Group Co's annualizedNet Income for the quarter that ended in Dec. 2025 was $1,048 Mil.
Sinopharm Group Co's average Total Assets over the quarter that ended in Dec. 2025 was $56,981 Mil. Therefore, Sinopharm Group Co's annualized ROA % for the quarter that ended in Dec. 2025 was 1.84%.
The historical rank and industry rank for Sinopharm Group Co's ROA % or its related term are showing as below:
SHTDF'
s ROA % Range Over the Past 10 Years
Min: 1.79 Med: 2.45 Max: 3.28
Current: 1.8
During the past 13 years, Sinopharm Group Co's highest ROA % was 3.28%. The lowest was 1.79%. And the median was 2.45%.
SHTDF's ROA % is ranked worse than 58.33% of 120
companies
in the Medical Distribution industry
Industry Median: 2.23
vs SHTDF: 1.80
Sinopharm Group Co (OTCPK:SHTDF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sinopharm Group Co ROA % Related Terms
Sinopharm Group Co ROA % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's ROA % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sinopharm Group Co (SHTDF) has a ROA % of 1.84% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sinopharm Group Co and its competitors. This is 25% below median its historical median of 2.45. Over the past decade, Sinopharm Group Co's ROA % has ranged from 1.79 to 3.28. According to the industry distribution chart, Sinopharm Group Co ranks #70 out of 120 companies in the Medical Distribution industry, placing it in the top 58.3%.
Is Sinopharm Group Co's ROA % too high?
Sinopharm Group Co's current ROA % of 1.84% is 25% below median its 10-year median of 2.45. Over the past 10 years, this metric has ranged from a low of 1.79 to a high of 3.28. The Medical Distribution industry median ROA % is 2.23. Sinopharm Group Co's value of 1.84% is 17.5% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #70 out of 120 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #70 out of 120 companies for ROA %. This places Sinopharm Group Co in the lower half of its industry. The industry median ROA % is 2.23. Sinopharm Group Co's value of 1.84% is 17.5% below this benchmark. Historically, Sinopharm Group Co's own ROA % has ranged from 1.79 to 3.28 over the past decade. While the company's 10-year median is 2.45 vs. the industry median of 2.23, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.23, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current ROA % of 1.84% is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median ROA % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current ROA % is 1.84%, which is 25% below median its own 10-year median of 2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current ROA % is 1.84%, which is 25% below median its 10-year median of 2.45 and 17.5% below the Medical Distribution industry median of 2.23. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current ROA % is 1.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
ROA %: 1.84% (25% below median its 10-year median of 2.45)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 17.5% below the Medical Distribution median (#70 of 120)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
